Portable Plasmonic Nanochip for Fast-On-Site Cardiac Troponin Biomarker Quantitative Diagnostic Test
Experimental - Demonstration Project
Results
Execution Stage 1 – Fabrication of Plasmonic Nanoplatforms based on Glass Substrates (01.11.2020 – 31.12.2020)
► Controlled synthesis of colloidal gold nanobipyramids (AuBPs) with controlled optical response from 673 to 844 nm with high tunability and reproducibility.
► Fabrication of the plasmonic nanoplatform by the self-assembly of the colloidal AuBPs onto silanized glass substrates.
► Optical and morphological characterization of the as-fabricated plasmonic nanoplatform as well as its validation as an efficient nanosensor using both LSPR and SERS techniques.
►Creation of the designated webpage of the NanoFastDiag project.
Execution Stage 2 – Fabrication of the Final Nanochip (01.01.2021 – 31.12.2021)
► Fabrication of the desired Y-shaped microfluidic channels by employing a laser cutter.
► Integration of the plasmonic AuBPs-based nanoplatform developed in Execution Stage 1 in the microfluidic chip followed by the assembly of the final microfluidic plasmonic chip.
► Functionalization of the as-developed microfluidic plasmonic chip with molecular recognition elements specific to/suitable for the final detection application.
► Validation of the as-developed microfluidic plasmonic chip for the detection of the cardiac troponin I biomarker by employing two spectroscopic techniques, specifically LSPR and SERS, as well as by thermoplasmonic sensing.
► Sampling of biological probes from adult and paediatric pacients.
Execution Stage 3 – Validation of the Final Plasmonic Nanochip for the Rapid On-site cTnI Biomarker Detection from Real Samples (01.01.2022 – 31.10.2022)
► Optimization of the functionalization of the as-developed microfluidic plasmonic chip with molecular recognition elements suitable for the final detection application.
► cTnI detection using the currently available commercial detection techniques.
►Validation of the as-developed microfluidic plasmonic chip for the multimodal detection of the cardiac troponin I biomarker from biological samples via portable LSPR – SERS – thermal biosensing.
► Comparison of the results obtained using the as-developed portable and miniaturized microfluidic plasmonic nanochip with the cTnI values resulted from the current testing kits.
In conclusion, NanoFastDiag developed and implemented an innovative technique, precisely a new concept of a robust lab-on-a-chip type plasmonic nanosensor with capabilities for efficient, specific and real time multimodal detection of the cardiac troponin I biomarker (cTnI) proving direct application in the diagnostic of cardiac diseases. Due to the specificity and sensitivity of this biomarker, the rise or modification of its values represents an indicator for the early diagnosis of small myocardial infarcts, which would be difficult to diagnose in other conditions. In this clinical context, NanoFastDiag successfully exploited the unique optical properties of gold nanobipyramids (AuBPs), employed herein both as optical nanoantenna’s as well as efficient thermoplasmonic generators, by their controlled integration in microfluidic channels for the portable real time detection of the cardiac cTnI biomarker from biological samples – using several designs of microfluidic channels.
Funded by
Contact
CS I Habil Dr Monica FOCSANE-mail: monica.iosin@ubbcluj.roTel: 0264454554/116 Nanobiophotonics and Laser Microspectroscopy Center Babes-Bolyai University, 42 Treboniu Laurian, 400271, Cluj Napoca, Romania